

SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Under Rule 14a-12

Enzo Biochem, Inc.

(Name of Registrant as Specified In Its Charter)

Harbert Discovery Fund, LP
Harbert Discovery Co-Investment Fund I, LP
Harbert Discovery Fund GP, LLC
Harbert Discovery Co-Investment Fund I GP, LLC
Harbert Fund Advisors, Inc.
Harbert Management Corporation
Jack Bryant
Kenan Lucas
Raymond Harbert
Fabian Blank
Peter J. Clemens, IV


(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rule 14a-6(i)(4) and 0-11.
 - 1) Title of each class of securities to which transaction applies:
 - 2) Aggregate number of securities to which transaction applies:
 - 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
 - 4) Proposed maximum aggregate value of transaction:
 - 5) Total fee paid:
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - 1) Amount Previously Paid:
 - 2) Form, Schedule or Registration Statement No.:
 - 3) Filing Party:
 - 4) Date Filed:

On January 16, 2020, Fabian Blank, one of Harbert Discovery Fund, LP, Harbert Discovery Co-Investment Fund I, LP, and certain of their affiliates' (collectively "Harbert") nominees, posted a link to a press release on social media regarding Glass, Lewis & Co.'s voting recommendations to shareholders for the upcoming annual meeting of shareholders of Enzo Biochem, Inc. A screenshot of his LinkedIn post is attached herewith as Exhibit 1 and a screenshot of his Twitter post is attached herewith as Exhibit 2.

LinkedIn



Fabian Blank
Healthcare/HealthTech: NED, Advisor, Investor
[View public profile](#)
[+ Follow](#)
963 Followers

52 Posts


1 Article

Fabian Blank
Healthcare/HealthTech: NED, Advisor, Investor
2h · Edited

Update: **Glass, Lewis & Co.**, a leading proxy advisory services firm, published their assessment of the situation at Enzo: supports largest shareholder's case for change and the need for "fresh perspectives in the boardroom".

>> Important information about participants in a proxy solicitation can be found here: <https://lnkd.in/g-bqQtB> <<

[#enzo](#) [#cureenzo](#) [#value](#) [#growth](#) [#governance](#) [#factsmatter](#) [#biotech](#) [#lifesciences](#) [#healthcare](#)



Harbert Management Corporation

Glass Lewis Recommends Shareholders Vote For the Election of Both Harbert...
[businesswire.com](#)

[Like](#) [Comment](#) [Share](#)

Home Messages Search Twitter Post an account? Log in

Fabian Blank @fabianb Follow

leading proxy advisor @GlassLewis published their view on Enzo: supports shareholder's case + need for "fresh perspectives" #cureenzo #value #healthcare

[information about participants in a proxy solicitation can be found here: [lnkd.in/g-bqQtB](https://www.linkedin.com/company/glass-lewis)]

Glass Lewis Recommends Shareholders Vote For the Election of Both Harber...
Harber Discovery Fund, LP and Harber Discovery Co-Investment Fund I, LP (collectively "HDF"), the beneficial owners of more than 11.8% of the outside [glasslewis.com](https://www.glasslewis.com)

11:35 AM - 16 Jan 2020

2 Retweets 3 Likes

© 2020 Twitter. About · Help Center · Terms · Privacy Policy · Cookies · Advertise